#EuroPCR 2024 is fast approaching and to prepare for the Course, this year we have prepared the #EIJchallenge , which will put your knowledge of the journal and cardiovascular medicine to the test.

It will unfold in 2 parts: an online challenge on social media (Level 1) and then…

Intravascular imaging (IVI)-guided percutaneous coronary intervention (PCI), is associated with reduction in any-type and ischemia-driven target lesion revascularization compared with invasive coronary angiography (ICA)-guided PCI: A network meta-analysis.ahajournals.org/doi/10.1161/CI…

Percutaneous treatments for pulmonary embolism are emerging as alternatives to conventional therapies with recent data, and safety profiles endorsing a shift towards a “primary percutaneous pulmonary intervention” strategy, similar to that for ST-elevation myocardial infarction.

Various definitions for diagnosing periprocedural myocardial infarction (PMI) and injury have been developed and tested over time, posing challenges in clinical practice and complicating trial design and interpretation.

The 5th Universal definition of myocardial infarction will…

Targeting residual inflammatory risk across the full spectrum of atherosclerotic disease is the next frontier for atherosclerosis treatment and prevention.

In patients with residual inflammatory risk, based on guidelines, low-dose colchicine can be added to statin therapy as…

📣Trial sequential analysis methodology for interpreting meta-analytical findings

👏Antonio Greco Davide Capodanno

Link🖇️:ejinme.com/article/S0953-…

Jacopo Imberti monica solbiati

This study of 25 trials and 17128 patients, now ahead of print in Circulation, employs frequentist random-effects network meta-analyses and Bayesian random-effects models to compare optical coherence tomography (OCT), intravascular ultrasound (IVUS), and invasive coronary…

Several Factor XI inhibitors have undergone design, testing, and progression to phase 2 clinical trials, demonstrating a generally favorable safety and tolerability profile. However, validation through large-scale phase 3 trials with adequate power to assess safety and efficacy…

This review comprehensively examines FXI inhibitors, delving into individual classes, evaluating the latest evidence from RCTs, and discussing future perspectives bit.ly/3O35QPR

Stefan Agewall Felice Gragnano Davide Capodanno Giovanni Occhipinti Antonio Greco #EHJPharmacotherapy

Where are we with drug-coated balloons (DCB) in PCI? Five thoughts.

1) The use of DCB in patients with in-stent restenosis, especially of a bare metal stent, is well established and evidence-based (now also in the US).

2) Conversely, DCB use in de novo disease lacks compelling…

Factor XI (FXI) has recently emerged as a pivotal contributor to intraluminal thrombus formation and growth, playing a limited role in sealing vessel wall injuries. Nevertheless, the halt of the OCEANIC-AF trial has raised uncertainties about the future of this class. As…

'Ok, nice meta-analysis, but is it conclusive?'

Each time (or perhaps one less than one) during my career when I included a Trial Sequential Analysis (TSA) to accompany a meta-analysis, I encountered resistance from reviewers and editors who asked me to remove it. Reasons cited…

Asociación de las características del ensayo con la publicación simultánea y su impacto en citas y menciones: un estudio transversal #REC #AheadOfPrint Marco Spagnolo, Antonio Greco, Davide Capodanno revespcardiol.org//es-asociacion…

Factor XI inhibitors consistently reduced the activity of factor XI and were not associated with increased rates of bleeding; however, no clear benefits have been demonstrated to date in most clinical scenarios

In the PACIFIC-AMI trial, adding asundexian to DAPT in patients with recent acute MI was associated with similar rates of bleeding and major adverse cardiovascular events compared to placebo

In patients with acute ischemic stroke, asundexian and milvexian were associated with similar rates to placebo of the composite of ischemic stroke or covert brain infarct detected by MRI; however, a null effect on covert brain infarct may have influenced these results

The PACIFIC-AF and AZALEA-TIMI 71 trials showed improved safety profile of asundexian and abelacimab compared to DOACs, but concerns about the efficacy of factor XI inhibitors in atrial fibrillation arose after the premature termination of the OCEANIC-AF trial

In two randomized trials of patients with end-stage renal disease, adverse events were similar between patients on factor XI inhibitors and placebo, and were adjudicated to be unrelated to the study drug

In trials of orthopaedic surgery, most doses of factor XI inhibitors reduced the occurrence of venous thromboembolism compared to enoxaparin

Great overview on FXI inhibition by Antonio Greco - wonderful slides #BSTH2023